|
1
|
Wang J, Xia Y, Zuo Q and Chen T: Molecular
mechanisms underlying the antimetastatic activity of bufalin. Mol
Clin Oncol. 8:631–636. 2018.PubMed/NCBI
|
|
2
|
Dai XY, Zhou BF, Xie YY, Lou J and Li KQ:
Bufalin and 5-fluorouracil synergistically induce apoptosis in
colorectal cancer cells. Oncol Lett. 15:8019–8026. 2018.PubMed/NCBI
|
|
3
|
Cui X, Inagaki Y, Xu H, Wang D, Qi F,
Kokudo N, Fang D and Tang W: Anti-hepatitis B virus activities of
cinobufacini and its active components bufalin and cinobufagin in
HepG2.2.15 cells. Biol Pharm Bull. 33:1728–1732. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Lu CX, Nan KJ and Lei Y: Agents from
amphibians with anticancer properties. Anticancer Drugs.
19:931–939. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Qi F, Li A, Inagaki Y, Kokudo N, Tamura S,
Nakata M and Tang W: Antitumor activity of extracts and compounds
from the skin of the toad Bufo bufo gargarizans Cantor. Int
Immunopharmacol. 11:342–349. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Jiang Y, Zhang Y, Luan J, Duan H, Zhang F,
Yagasaki K and Zhang G: Effects of bufalin on the proliferation of
human lung cancer cells and its molecular mechanisms of action.
Cytotechnology. 62:573–583. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Li M, Yu X, Guo H, Sun L, Wang A, Liu Q,
Wang X and Li J: Bufalin exerts antitumor effects by inducing cell
cycle arrest and triggering apoptosis in pancreatic cancer cells.
Tumor Biol. 35:2461–2471. 2014. View Article : Google Scholar
|
|
8
|
Qiu DZ, Zhang ZJ, Wu WZ and Yang YK:
Bufalin, a component in Chansu, inhibits proliferation and invasion
of hepatocellular carcinoma cells. BMC Complement Altern Med.
13:185–195. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Qiu YY, Hu Q, Tang QF, Feng W, Hu SJ,
Liang B, Peng W and Yin PH: MicroRNA-497 and bufalin act
synergistically to inhibit colorectal cancer metastasis. Tumor
Biol. 35:2599–2606. 2014. View Article : Google Scholar
|
|
10
|
Xie CM, Chan WY, Yu S, Zhao J and Cheng
CH: Bufalin induces autophagy-mediated cell death in human colon
cancer cells through reactive oxygen species generation and JNK
activation. Free Radic Biol Med. 51:1365–1375. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Xie XB, Yin JQ, Wen LL, Gao ZH, Zou CY,
Wang J, Huang G, Tang QL, Colombo C, He WL, Jia Q and Shen JN:
Critical role of heat shock protein 27 in bufalin-induced apoptosis
in human osteosarcomas: A proteomic-based research. PLoS One.
7:e473752012. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Yin PH, Liu X, Qiu YY, Cai JF, Qin JM, Zhu
HR and Li Q: Anti-tumor activity and apoptosis-regulation
mechanisms of bufalin in various cancers: New hope for cancer
patients. Asian Pac J Cancer Prev. 13:5339–5343. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Takai N, Kira N, Ishii T, Yoshida T,
Nishida M, Nishida Y, Nasu K and Narahara H. Bufalin: a traditional
oriental medicine, induces apoptosis in human cancer cells. Asian
Pac J Cancer Prev. 13:399–402. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Zhang DM, Feng LX, Liu M, Jin WH, Luo J,
Nie AY, Zhou Y, Li Y, Wu WY, Jiang BH, et al: Possible
target-related proteins and signal network of bufalin in A549 cells
suggested by both iTRAQ-based and label-free proteomic analysis.
Proteomics. 16:935–945. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Wu SH, Hsiao YT, Chen JC, Lin JH, Hsu SC,
Hsia TC, Yang ST, Hsu WH and Chung JG: Bufalin alters gene
expressions associated DNA damage, cell cycle and apoptosis in
human lung cancer NCI-H460 cells in vitro. Molecules. 19:6047–6057.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Jiang L, Zhao MN, Liu TY, Wu XS, Weng H,
Ding Q, Shu YJ, Bao RF, Li ML, Mu JS, et al: Bufalin induces cell
cycle arrest and apoptosis in gallbladder carcinoma cells. Tumour
Biol. 35:10931–10941. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Hong SH and Choi YH: Bufalin induces
apoptosis through activation of both the intrinsic and extrinsic
pathways in human bladder cancer cells. Oncol Rep. 27:114–120.
2012.PubMed/NCBI
|
|
18
|
Dong Y, Yin S, Li J, Jiang C, Ye M and Hu
H: Bufadienolide compounds sensitize human breast cancer cells to
TRAIL-induced apoptosis via inhibition of STAT3/Mcl-1 pathway.
Apoptosis. 16:394–403. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Zhu Z, Li E and Liu Y, Gao Y, Sun H, Wang
Y, Wang Z, Liu X, Wang Q and Liu Y: Bufalin induces the apoptosis
of acute promyelocytic leukemia cells via the downregulation of
survivin expression. Acta Haematol. 128:144–150. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Zhai X, Lu J, Wang Y, Fang F, Li B and Gu
W: Reversal effect of bufalin on multidrug resistance in K562/VCR
vincristine-resistant leukemia cell line. J Tradit Chin Med.
34:678–683. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Wang LP, Zhao YN, Sun X and Gao RL:
Effects of bufalin on up-regulating methylation of Wilm's tumor 1
gene in human erythroid leukemic cells. Chin J Integr Med.
23:288–294. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Jing Y, Watabe M, Hashimoto S, Nakajo S
and Nakaya K: Cell cycle arrest and protein kinase modulating
effect of bufalin on human leukemia ML1 cells. Anticancer Res.
14:1193–1198. 1994.PubMed/NCBI
|
|
23
|
Li D, Qu X, Hou K, Zhang Y, Dong Q, Teng
Y, Zhang J and Liu Y: PI3K/Akt is involved in bufalin-induced
apoptosis in gastric cancer cells. Anticancer Drugs. 20:59–64.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Yeh JY, Huang WJ, Kan SF and Wang PS:
Effects of bufalin and cinobufagin on the proliferation of androgen
dependen and independent prostate cancer cells. Prostate.
54:112–124. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Yu CH, Kan SF, Pu HF, Jea Chien E and Wang
PS: Apoptotic signaling in bufalin- and cinobufagin-treated
androgen-dependent and-independent human prostate cancer cells.
Cancer Sci. 99:2467–2476. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Han KQ, Huang G, Gu W, Su YH, Huang XQ and
Ling CQ: Anti-tumor activities and apoptosis-regulated mechanisms
of bufalin on the orthotopic transplantation tumor model of human
hepatocellular carcinoma in nude mice. World J Gastroenterol.
13:3374–3379. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Lan YL, Wang X, Lou JC, Xing JS, Yu ZL,
Wang H, Zou S, Ma X and Zhang B: Bufalin inhibits glioblastoma
growth by promoting proteasomal degradation of the
Na+/K+ -ATPase α1 subunit. Biomed
Pharmacother. 103:204–215. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Choi KS: Autophagy and cancer. Exp Mol
Med. 44:109–120. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Naumann P, Fortunato F, Zentgraf H,
Büchler MW, Herr I and Werner J: Autophagy and cell death signaling
following dietary sulforaphane act independently of each other and
require oxidative stress in pancreatic cancer. Int J Oncol.
39:101–109. 2011.PubMed/NCBI
|
|
30
|
Rabinowitz JD and White E: Autophagy and
metabolism. Science. 330:1344–1348. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Lee J, Giordano S and Zhang J: Autophagy,
mitochondria and oxidative stress: Cross-talk and redox signalling.
Biochem J. 441:523–540. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Martinez-Borra J and Lopez-Larrea C:
Autophagy and self-defense. Adv Exp Med Biol. 738:169–184. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Anders HJ and Schlondorff DO: Innate
immune receptors and autophagy: Implications for autoimmune kidney
injury. Kidney Int. 78:29–37. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Ropolo A, Bagnes CI, Molejon MI, Lo Re A,
Boggio V, Gonzalez CD and Vaccaro MI: Chemotherapy and
autophagy-mediated cell death in pancreatic cancer cells.
Pancreatology. 12:1–7. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Guo XL, Li D, Hu F, Song JR, Zhang SS,
Deng WJ, Sun K, Zhao QD, Xie XQ, Song YJ, et al: Targeting
autophagy potentiates chemotherapy-induced apoptosis and
proliferation inhibition in hepatocarcinoma cells. Cancer Lett.
320:171–179. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Yousefi S and Simon HU: Autophagy in
cancer and chemotherapy. Results Probl Cell Differ. 49:183–190.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Tsai SC, Yang JS, Peng SF, Lu CC, Chiang
JH, Chung JG, Lin MW, Lin JK, Amagaya S, Wai-Shan, Chung C, et al:
Bufalin increases sensitivity to AKT/mTOR-induced autophagic cell
death in SK-HEP-1 human hepatocellular carcinoma cells. Int J
Oncol. 41:1431–1442. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Shen S, Zhang Y, Wang Z, Liu R and Gong X:
Bufalin induces the interplay between apoptosis and autophagy in
glioma cells through endoplasmic reticulum stress. Int J Biol Sci.
10:212–224. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Tsujimoto Y and Shimizu S: Another way to
die: Autophagic programmed cell death. Cell Death Differ. 12 Suppl
2:S1528–S1534. 2005. View Article : Google Scholar
|
|
40
|
Chen KK and Kovaríková A: Pharmacology and
toxicology of toad venom. J Pharm Sci. 56:1535–1541. 1967.
View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Rahman A and Fazal F: Blocking NF-κB: An
inflammatory issue. Proc Am Thorac Soc. 8:497–503. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Ye J, Chen S and Maniatis T: Cardiac
glycosides are potent inhibitors of interferon-β gene expression.
Nat Chem Biol. 7:25–33. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Wen L, Huang Y, Xie X, Huang W, Yin J, Lin
W, Jia Q and Zeng W: Anti-inflammatory and antinociceptive
activities of bufalin in rodents. Mediators Inflamm.
2014:1718392014. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Colombo MP and Mantovani A: Targeting
myelomonocytic cells to revert inflammation-dependent cancer
promotion. Cancer Res. 65:9113–9116. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Huang Y, Snuderl M and Jain RK:
Polarization of tumor-associated macrophages: A novel strategy for
vascular normalization and antitumor immunity. Cancer Cell. 19:1–2.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Huang Y, Yuan J, Righi E, Kamoun WS,
Ancukiewicz M, Nezivar J, Santosuosso M, Martin JD, Martin MR,
Vianello F, et al: Vascular normalizing doses of antiangiogenic
treatment reprogram the immunosuppressive tumor microenvironment
and enhance immunotherapy. Proc Natl Acad Sci USA. 109:17561–17566.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Hu Q, Liang B, Sun Y, Guo XL, Bao YJ, Xie
DH, Zhou M, Duan YR, Yin PH and Peng ZH: Preparation of
bufalin-loaded pluronic polyetherimide nanoparticles, cellular
uptake, distribution, and effect on colorectal cancer. Int J
Nanomedicine. 9:4035–4041. 2014.PubMed/NCBI
|
|
48
|
Yang Z, Teng Y, Wang H and Hou H:
Enhancement of skin permeation of bufalin by limonene via reservoir
type transdermal patch: Formulation design and biopharmaceutical
evaluation. Int J Pharm. 447:231–240. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Pettit GR, Houghton LE, Knight JC and
Bruschwe F: Synthesis of bufalin. J Chem Soc D Chem Commun.
2:93–94. 1970. View Article : Google Scholar
|
|
50
|
Yuan XF, Tian HY, Li J, Jin L, Jiang ST,
Liu KW, Luo C, Middleton DA, Esmann M, Ye WC and Jiang RW:
Synthesis of bufalin derivatives with inhibitory activity against
prostate cancer cells. Nat Prod Res. 28:843–847. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Liu T, Yuan X, Jia T, Liu C, Ni Z, Qin Z
and Yuan Y: Polymeric prodrug of bufalin for increasing solubility
and stability: Synthesis and anticancer study in vitro and in vivo.
Int J Pharm. 506:382–393. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Lei M, Xiao Z, Ma B, Chen Y, Liu M, Liu J,
Guo D, Liu X and Hu L: Synthesis and biological evaluation of
bufalin-3-yl nitrogen-containing-carbamate derivatives as
anticancer agents. Steroids. 108:56–60. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Liu M, Feng LX, Sun P, Liu W, Wu WY, Jiang
BH, Yang M, Hu LH, Guo DA and Liu X: A novel bufalin derivative
exhibited stronger apoptosis-inducing effect than bufalin in A549
lung cancer cells and lower acute toxicity in mice. PLoS One.
11:e01597892016. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Sun P, Feng LX, Zhang DM, Liu M, Liu W, Mi
T, Wu WY, Jiang BH, Yang M, Hu LH, et al: Bufalin derivative BF211
inhibits proteasome activity in human lung cancer cells in vitro by
inhibiting β1 subunit expression and disrupting proteasome
assembly. Acta Pharmacol Sin. 37:908–918. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Su YH and Nu X: Evaluation of
pharmacodynamic effect of pharmaceutical agents of Chan Su. J
Beijing Univ TCM. 24:51–54. 2001.
|
|
56
|
Su YH, Huang XQ, Zhang DZ, Zhang YN, Xie
JM and Linh CQ: HPLC separation and determination of bufadienolide
in cinobufacini injection. Chin Trad Patent Med. 25:24–27.
2003.
|
|
57
|
Meng Z, Yang P, Shen Y, Bei W, Zhang Y, Ge
Y, Newman RA, Cohen L, Liu L, Thornton B, et al: Pilot study of
huachansu in patients with hepatocellular carcinoma, nonsmall-cell
lung cancer, or pancreatic cancer. Cancer. 115:5309–5318. 2009.
View Article : Google Scholar : PubMed/NCBI
|
